Dexcom, which sells wearable sensors that track glucose levels, increased second-quarter 2026 sales by 13.1% from a year earlier while operating profit rose 49.7%. Sales growth and better manufacturing economics outweighed higher inventory charges, which management linked primarily to the planned end of manufacturing its older G6 sensor system. Operating profit measures what remains after production, research, selling and administrative expenses, before interest and taxes. That improvement strengthens the business, although more finished products in inventory and substantial share repurchases constrain the cash available for its transition.
Reporting basis: DexCom, Inc. and its wholly owned subsidiaries; unaudited consolidated U.S. GAAP accounts. The quarter covers April 1–June 30, 2026, compared with the same quarter of 2025. First-half figures cover January 1–June 30 in each year. Balance-sheet comparisons are June 30, 2026 versus December 31, 2025. Form 10-Q filed July 30, 2026; accession 0001093557-26-000143; CIK 0001093557. Information cutoff: July 30, 2026. Research checked October 6, 2026; later developments are outside this assessment.
Source: SEC filing record, July 30, 2026; Dexcom second-quarter 2026 Form 10-Q, cover, financial statements and Note 1, pp. 4–11.
1. More sales now leave more money after production costs
Dexcom’s profit improvement is visible in reported results, even after higher inventory charges. Revenue rose 13.1% in the quarter, while cost of sales rose only 2.2%. Cost of sales includes production costs and inventory write-downs. The share of revenue left after these costs—gross margin—increased, leaving more of each sales dollar to pay for research, marketing and other expenses.
The pattern also holds across the first six months. Sales increased 14.0%, while operating profit increased 65.6%. That broader comparison matters because a single quarter can be affected by shipment dates or the timing of spending.
| Consolidated results; dollars in millions except per-share amounts and margins | Second quarter 2025 | Second quarter 2026 | First half 2025 | First half 2026 |
|---|---|---|---|---|
| Revenue | 1,157.1 | 1,308.4 | 2,193.1 | 2,500.3 |
| Cost of sales | 468.3 | 478.4 | 915.3 | 920.0 |
| Gross profit | 688.8 | 830.0 | 1,277.8 | 1,580.3 |
| Gross margin, calculated | 59.5% | 63.4% | 58.3% | 63.2% |
| Research and development | 148.2 | 153.0 | 293.4 | 298.3 |
| Selling, general and administrative expense | 328.0 | 358.7 | 638.1 | 708.4 |
| Operating profit | 212.6 | 318.3 | 346.3 | 573.6 |
| Operating margin, calculated | 18.4% | 24.3% | 15.8% | 22.9% |
| Net income | 179.8 | 249.1 | 285.2 | 448.6 |
| Diluted earnings per share, dollars | 0.45 | 0.64 | 0.71 | 1.15 |
Source: 2026 Form 10-Q, consolidated statements of operations, p. 5. Margins are calculated from the reported amounts.
Management attributes the improvement to higher sensor sales, benefits from G7 15 Day, better manufacturing efficiency, higher production volumes and a more favorable manufacturing mix. Producing more usable sensors spreads factory costs across more products. The filing also discusses additional quality testing and material validation relative to the prior year, but provides no dollar breakdown of these effects.
The quarterly profit bridge is straightforward. Gross profit increased $141.2 million, while research and development plus selling, general and administrative expenses together increased $35.5 million. The remaining $105.7 million explains the entire increase in operating profit. This is stronger evidence of operating improvement than a rise in earnings caused mainly by a tax benefit or investment gain.
Spending still grew where management wanted to support the business. Of the $30.7 million quarterly increase in selling, general and administrative costs, management identified $12.1 million for advertising and marketing, $6.7 million for compensation and related costs, and $6.3 million for facilities. Research spending was nearly flat because of project timing; the filing does not establish a retreat from product development.
Source: 2026 Form 10-Q, management discussion, pp. 31–35.
A longer comparison puts the rebound in perspective. Second-quarter gross margin was 62.4% in 2024, fell to 59.5% in 2025 and reached 63.4% in 2026. Some of the latest improvement therefore restores ground lost a year earlier. Still, the 2026 margin exceeds the 2024 level, so the result is more than a return to the immediately preceding baseline.
| Same-quarter historical check; consolidated, dollars in millions | Second quarter 2024 | Second quarter 2025 | Second quarter 2026 |
|---|---|---|---|
| Revenue | 1,004.3 | 1,157.1 | 1,308.4 |
| Gross profit | 626.7 | 688.8 | 830.0 |
| Gross margin, calculated | 62.4% | 59.5% | 63.4% |
Sources: Dexcom July 30, 2025 results, Table B; 2026 Form 10-Q, p. 5.
This history supports a manufacturing recovery and improvement, not an assumption that margins will rise every quarter. The immediate business benefit is that Dexcom can fund more activity from each dollar of sales, provided that product quality and customer demand hold up.
2. Growth comes from both markets, but access shapes the money collected
International growth adds breadth, while the United States still supplies most of the sales increase. U.S. revenue rose $92.4 million in the quarter, and international revenue rose $58.9 million. International sales grew faster, but the larger U.S. business contributed about 61% of the total increase.
| Revenue by geography and channel; dollars in millions | Second quarter 2025 | Second quarter 2026 | Calculated growth |
|---|---|---|---|
| United States | 841.0 | 933.4 | 11.0% |
| International | 316.1 | 375.0 | 18.6% |
| Distributor sales, worldwide | 977.8 | 1,102.4 | 12.7% |
| Direct sales, worldwide | 179.3 | 206.0 | 14.9% |
Reporting basis: Geography and channel are two views of the same revenue; the four rows must not be added together. Dexcom reports one operating segment and does not disclose separate geographic operating profits.
Source: 2026 Form 10-Q, Note 8, pp. 25–26.
Management says more customers using disposable sensors was the main driver. Revenue per customer also benefited from changes in who pays for the sensors, such as insurers, and how much customers use them. Changes in sales channels, products sold and eligibility for rebates partly offset those benefits. Selling more sensors and recording more revenue per customer are different ways to grow; neither establishes a broad increase in list prices or means the cash has already been collected.
The filing cites approximately 600,000–700,000 net customer additions during 2025, excluding Stelo. That is historical context for the larger customer base, not a disclosure of additions during this quarter. It provides no complete current-quarter bridge dividing growth among new users, usage, prices and individual products.
Source: 2026 Form 10-Q, management discussion of revenue, pp. 31 and 34.
Currency movements helped reported growth, but do not explain most of it. In its earnings release, Dexcom calculated quarterly growth of 12% after excluding $9.9 million of currency effects and $0.2 million of acquired non-glucose-monitoring revenue. This company-defined comparison supports the conclusion that the main increase came from the operating business.
Source: Dexcom July 30, 2026 results, financial highlights and organic-revenue footnote. The company's “organic” measure is non-GAAP.
Distributors accounted for 84.3% of quarterly revenue. That creates a gap between a shipment to a business customer and a sensor being used by a patient. Changes in distributor stocking can therefore affect the timing of reported sales, although this filing does not quantify a channel-inventory contribution to growth.
Payment arrangements also affect the economics. Dexcom estimates discounts owed under pharmacy and other payor programs when recording a sale. It can collect an invoice before settling the related discount, known as a rebate. These obligations are already reflected in revenue estimates; paying them later uses cash without creating the same expense a second time.
Source: Dexcom 2025 Form 10-K, Note 1, “Revenue Recognition,” pp. F-15–F-16, and “Critical Accounting Estimates—Pharmacy Rebates.”
That process makes access commercially valuable but financially complex. Coverage can bring more users, while rebates reduce the amount ultimately retained. Continued growth is most useful when it produces both wider adoption and satisfactory receipts after those commitments are paid.
3. The G6 transition raises costs even as the factory business improves
Inventory is the clearest counterweight to the stronger profit result. Inventory rose 15.5% from year-end to $726.4 million. Completed products drove the increase, while raw materials declined.
| Consolidated inventory; dollars in millions | December 31, 2025 | June 30, 2026 | Change |
|---|---|---|---|
| Raw materials | 257.6 | 232.7 | -24.9 |
| Work in process | 105.0 | 107.0 | 2.0 |
| Finished goods | 266.5 | 386.7 | 120.2 |
| Total inventory | 629.1 | 726.4 | 97.3 |
Source: 2026 Form 10-Q, Note 3, “Inventory,” p. 16.
Finished goods increased 45.1%. Building stock can help serve customers during a product change, but the filing does not identify how much of this balance belongs to G6, G7 or other products. It cannot establish whether the increase is an intentional supply buffer, slow-moving stock or a combination.
The expense for inventory expected to lose value also rose. Dexcom recorded $45.6 million of inventory reserve charges in the quarter, compared with $8.8 million a year earlier. Across the first half, charges were $84.2 million versus $37.0 million. These are expenses recognized during the periods, not the total reserve balance at either date.
The note lists quality-control findings, expected demand, product innovation and the planned end of G6 manufacturing as relevant factors. Management links the higher excess and obsolete inventory charges primarily to that planned discontinuation. It does not assign all reserve expense to G6 or provide an exact G6-only amount.
Source: 2026 Form 10-Q, Note 3, p. 16; management discussion, pp. 31 and 34.
These charges remain inside reported production costs. The $36.8 million year-over-year increase in quarterly charges therefore worked against the margin improvement already shown. That is strong evidence that favorable manufacturing and sales effects were substantial, although it does not justify treating inventory losses as a cost that will disappear.
Dexcom is also putting money into the next stage of production. First-half cash spending on property and equipment was $161.3 million. Net property and equipment rose only $17.3 million to $1.58 billion because the balance reflects depreciation and other changes as well as new investment. Construction in progress reached $614.4 million, showing that a substantial amount remains tied up in projects not yet transferred into completed asset categories.
Management identifies manufacturing facilities, equipment and office space as spending purposes, including its international manufacturing footprint. These disclosures support an expansion and operating-infrastructure purpose, but provide no reliable split between maintenance and growth spending. Comparing spending with depreciation would not supply that missing split.
Intangible assets—such as acquired technology—rose $30.8 million to $101.6 million. A second-quarter acquisition added $48.7 million of gross intangible assets and was accounted for as a purchase of assets, rather than a business combination. Amortization partly offset the addition. The cash-flow statement separately reports $41.2 million paid for an acquisition, net of acquired cash; that cash amount should not be forced to equal the gross asset recorded.
Goodwill was essentially unchanged at $24.1 million. Other assets fell $5.0 million, including an $8.5 million decline in non-marketable equity investments. These holdings involve companies whose shares do not have a readily quoted public market price, and their losses can affect earnings separately from the sensor business.
Source: 2026 Form 10-Q, balance sheet, p. 4; cash-flow statement, p. 9; Note 3, pp. 17–18; liquidity discussion, pp. 36–38.
The transition will be more convincing if finished goods turn into sales without further large write-downs. For now, Dexcom has improved reported profitability while absorbing a real product-transition cost, but has also committed more cash to stock and unfinished facilities.
4. Strong first-half cash flow includes a large timing benefit
Noncash adjustments explain most of the gap between operating cash flow and profit; payment timing also helped. First-half operating cash flow—the cash generated by day-to-day business—was $794.8 million, up $308.0 million. It exceeded net income by $346.2 million: $229.4 million came from adjustments for expenses and other items that did not use operating cash in the period, and $116.8 million came from changes in operating assets and liabilities. Receivables still absorbed cash, but much less than a year earlier.
| Profit-to-cash reconciliation; first half, dollars in millions | 2025 | 2026 |
|---|---|---|
| Net income | 285.2 | 448.6 |
| Noncash adjustments, calculated total | 178.8 | 229.4 |
| Changes in operating assets and liabilities, calculated net | 22.8 | 116.8 |
| Operating cash flow | 486.8 | 794.8 |
| Cash purchases of property and equipment | 181.1 | 161.3 |
| Free cash flow, calculated | 305.7 | 633.5 |
Reporting basis: Free cash flow here means operating cash flow less cash purchases of property and equipment. It is not a GAAP subtotal. It excludes acquisitions and does not deduct unpaid equipment purchases. Capital spending is displayed as a positive use of cash.
Source: 2026 Form 10-Q, consolidated cash-flow statement, p. 9. Components of the calculated subtotals appear in the calculation notes below.
Depreciation and amortization spread the cost of equipment and acquired assets across the periods they benefit. They reduce current profit even though the related cash payment may occur in another period. Share compensation also reduces profit without an immediate operating cash payment; adding these expenses back helps explain why operating cash flow exceeds profit.
The biggest favorable timing change was in customer receivables—the amounts customers still owed. Their increase absorbed $47.5 million of cash, compared with $333.5 million a year earlier. Dexcom thus had $286.0 million less cash tied up in new receivables during this half. Management attributes the improvement mainly to sales and collection timing; it does not establish a permanent reduction in how long customers take to pay.
Other movements partly offset that benefit. Inventory absorbed $101.6 million, versus $12.3 million previously. Payables and accrued liabilities supplied $258.0 million, less than the prior $359.4 million contribution. Payroll-related balances used $32.1 million after providing $15.3 million a year earlier.
Together, all operating-asset and liability movements improved cash flow by $94.0 million. Higher profit contributed $163.4 million of the total cash-flow increase, and changes in noncash adjustments contributed $50.6 million. The bridge reconciles exactly to the $308.0 million improvement.
Source: 2026 Form 10-Q, pp. 9 and 39.
The balance sheet makes the payment obligations more concrete. Accrued rebates rose $164.4 million to $1.652 billion, while trade payables rose $79.5 million to $423.8 million. Most of the combined $2.192 billion payables and accruals balance therefore represents rebates, not borrowing from banks or bondholders. The balance changes and cash-flow changes differ because they do not have identical accounting scope.
Receivables were $1.258 billion, up $41.6 million from year-end. Prepaid and other current assets fell $33.9 million, with income-tax receivables falling $48.3 million inside that total. The latter is a balance-sheet movement, not a separately disclosed cash-tax refund; the cash-flow statement groups several items together.
Source: 2026 Form 10-Q, balance sheet, p. 4; Note 3, pp. 17–18.
There is also an important quarterly limit to the upbeat first-half story. Management reports second-quarter operating cash flow of $269.2 million, down 11% year over year. Subtracting that from first-half cash flow gives $525.6 million for the first quarter. The filing does not provide a full stand-alone quarterly cash reconciliation, so it would be unwarranted to assign the second-quarter decline to one cause.
Source: 2026 Form 10-Q, “Key Highlights,” p. 29; consolidated cash-flow statement, p. 9.
The business is generating enough cash to fund its equipment purchases. The stronger first-half total nevertheless includes timing effects that can reverse when customers pay differently or accumulated rebates are settled. That distinction is crucial when deciding how much cash can be committed elsewhere.
5. Repurchases use nearly all the cash left after equipment spending
Dexcom can fund its present operations, but its repurchase pace consumes most of its internally generated surplus. After $161.3 million of cash equipment spending, first-half operating cash flow left $633.5 million. Cash treasury-stock purchases consumed $603.6 million, leaving $29.9 million before acquisitions and other uses.
Management says its long-range plan allocates at least half of operating cash flow after planned capital spending to repurchases. Buying shares reduces the number outstanding and can offset employee share issuance. In this half, however, treasury-stock cash payments were about 95% of the defined free cash flow, leaving little of that amount for the technology acquisition or employee tax settlements.
Source: 2026 Form 10-Q, cash-flow statement, p. 9; liquidity discussion, p. 37.
The cash balance alone gives an incomplete picture. Cash and equivalents increased $187.3 million, but short-term securities fell $239.0 million. Combined liquid funds therefore decreased $51.7 million to $1.947 billion. Turning securities into bank cash increases the cash line without creating new operating resources.
| Cash and restricted-cash reconciliation; first half 2026, dollars in millions | Amount |
|---|---|
| Opening cash, equivalents and restricted cash | 919.1 |
| Operating cash flow | 794.8 |
| Investing cash flow | 31.3 |
| Financing cash flow | -632.3 |
| Exchange-rate effect | -7.7 |
| Closing cash, equivalents and restricted cash | 1,105.2 |
Source: 2026 Form 10-Q, p. 9. Closing restricted cash is $0.2 million; the balance-sheet cash and equivalents figure is $1,105.0 million.
Investing cash flow was positive because security sales and maturities exceeded purchases by $235.3 million. That amount covered equipment purchases, the $41.2 million acquisition and $1.5 million of equity investments. Financing used cash primarily for treasury shares and $37.6 million of employee-award tax payments, partly offset by $12.7 million received from stock issuance.
Debt remains manageable in size, but repayment is concentrated. The outstanding convertible notes have $1.25 billion of principal due May 15, 2028 and a 0.375% annual coupon. Their contractual annual interest is approximately $4.7 million. The $1.243 billion balance-sheet carrying amount is lower than principal because it deducts unamortized issuance costs.
The earlier $1.21 billion notes were repaid in cash in November 2025. That repayment reduced interest costs and removed the shares previously assumed to arise from those notes when calculating diluted earnings per share. Repaying the notes in cash did not itself reduce actual shares outstanding. The remaining notes can convert into shares or cash under specified conditions, and no conversion occurred during the first half of 2026. Dexcom also holds capped-call contracts intended to reduce conversion-related dilution or cash costs above principal, subject to a cap; they do not remove the principal obligation.
Source: 2026 Form 10-Q, Note 4, pp. 19–21.
A separate revolving bank facility matures October 13, 2026. At June 30 it was undrawn, with $191.3 million available after letters of credit. Its expiry is a question of preserving backup funding, rather than refinancing a drawn $200 million loan. Dexcom reported compliance with its leverage and fixed-charge coverage covenants; the quarter does not quantify the remaining covenant cushion.
Borrowing under that facility would carry a variable reference rate plus a contractual spread. The term-benchmark and overnight-rate spreads range from 1.375% to 2.000%, depending on leverage, with an unused commitment fee of 0.175%–0.250%. Renewal terms should not be assumed to match the existing agreement.
Source: 2026 Form 10-Q, Note 4, p. 22.
Other commitments also need cash. Open purchase orders and contractual obligations totaled approximately $1.42 billion, mostly due within a year. These include ordinary operating and investment purchases; they should not simply be added to recorded liabilities as though all were separate financing debt. Operating lease liabilities totaled $103.3 million, and long-term finance-lease obligations were another $52.3 million.
The December 2025 lease schedule showed future operating and finance payments of $111.6 million and $83.4 million before discounting. Payments scheduled for 2026 were $25.9 million and $9.7 million; these are opening full-year commitments. The quarter reports no material change to lease obligations.
Sources: 2026 Form 10-Q, pp. 4, 18 and 38; 2025 Form 10-K, Note 5, lease maturity table.
Available cash and securities exceed note principal, but are also needed for rebates, inventory, facilities and other commitments. The $400 million remaining repurchase authorization is discretionary, not a mandatory liability. That flexibility gives management a practical way to protect funding if cash collection weakens or the transition requires more spending.
6. Net profit improves less than operating profit, while fewer shares help earnings per share
The earnings improvement comes mainly from operations; taxes and the share count change how much reaches the final figure. Quarterly net income rose 38.5%, slower than operating profit, because income outside the core business deteriorated.
Interest and dividend income fell $11.1 million to $16.9 million. Equity-investment losses increased by $9.6 million to $10.0 million. Other income turned into an expense, while lower interest expense provided a partial offset. Altogether, other income and expense moved from a $28.5 million benefit to a $0.8 million expense.
A lower tax rate cushioned that decline. The quarterly effective rate fell from 25.4% to 21.5%, calculated from tax expense and pretax profit. Management points to the Malaysia tax holiday and higher pretax income. The first-half rate was 23.6%, above management's 21.8% annual estimate. Management primarily attributes the difference to tax benefits on employee share awards falling short of the amounts previously recognized, net of the effect of executive compensation that cannot be deducted for tax purposes.
Source: 2026 Form 10-Q, pp. 5 and 18; Note 6, p. 23; management discussion, pp. 32 and 35.
Malaysia certified the tax-holiday milestones in July 2025, applying the benefit retroactively to January 2024. The conditional holiday can last up to 15 years. That history helps explain the first-half comparison; it does not make the current tax rate permanent.
Source: 2025 Form 10-K, Note 7, “Income Taxes,” p. F-39.
Diluted earnings per share increased from $0.45 to $0.64. The calculation uses both profit and a share count that assumes potentially dilutive securities convert into stock. Quarterly diluted shares fell from 408.2 million to 390.1 million, partly because assumed shares from convertible notes fell from 15.7 million to 7.7 million after the 2025 debt repayment. Lower ordinary weighted-average shares also helped.
The profit amount used to calculate diluted earnings per share adds back the notes’ interest expense after tax, because the calculation assumes those notes have converted into shares. This adjusted profit amount was $250.8 million in the second quarter of 2026, versus reported net income of $249.1 million. Dividing reported net income by the diluted share count would therefore miss part of the accounting calculation.
Source: 2026 Form 10-Q, Note 1, earnings-per-share reconciliation, p. 11.
Repurchases also explain why equity—the accounting amount left after liabilities are subtracted from assets—fell despite the profit. Accumulated profits, called retained earnings, rose by the full $448.6 million first-half net income. Additional paid-in capital, which records share-related contributions, rose $95.0 million through $82.3 million of share compensation and $12.7 million from employee stock purchases.
Against those increases, shares held by the company as treasury stock reduced equity by another $643.2 million. Accumulated other comprehensive income, which records certain gains and losses outside net income, declined $25.0 million, mainly from translating foreign operations into dollars.
The resulting equity balance was $2.621 billion, down $124.6 million. Issued shares increased from 410.7 million to 412.4 million, but outstanding shares declined from 384.8 million to 377.4 million. Repurchased and tax-withheld shares remain in treasury; they have not been retired. No dividend payment appears in the first-half cash-flow statement.
Source: 2026 Form 10-Q, pp. 4, 6–9; Note 7, p. 24.
The distinction between program purchases, cash payments and equity entries matters. Dexcom reports $600.0 million of program repurchases, $603.6 million of treasury-stock cash payments and $605.6 million of treasury purchases including excise tax in equity. These are different reported measures and are not interchangeable. Employee tax withholding adds a separate $37.6 million treasury-stock movement.
Share compensation is also a continuing cost, even though it does not immediately consume cash. Unrecognized award costs of $263.6 million were expected to enter expense over approximately 2.2 years. Buybacks reduce outstanding shares while ongoing awards partly replenish them. Higher operating profit, rather than the entire gain in earnings per share, is the clearest measure of improved sensor economics.
Source: 2026 Form 10-Q, statements of equity and cash flows, pp. 8–9; Note 7, p. 24.
7. Wider use offers growth, while quality remains a commercial constraint
Dexcom has evidence for expansion beyond insulin users, but evidence must become access and repeat use. Its strategy combines better sensors, links to insulin-delivery systems and tools for people managing metabolic health. G7 15 Day launched in late 2025, while Stelo, available without a prescription, launched in August 2024 for adults with prediabetes or type 2 diabetes who do not use insulin.
Longer wear and easier use can reduce the effort involved in monitoring. For the company, however, customer adoption must also produce acceptable revenue after rebates and manufacturing costs. The quarter does not disclose separate product profitability or enough Stelo data to measure its contribution independently.
Source: 2026 Form 10-Q, Note 8 and “Overview—Future Developments,” pp. 25–27.
The company-sponsored CONNECT trial strengthens the clinical argument for serving people with type 2 diabetes who do not use insulin. Dexcom's June 6 announcement described 283 randomized participants, with 265 completing the 26-week study and included in the key reported outcomes. Average A1C, a measure of longer-term glucose levels, fell 1.6 percentage points in the G7 group—0.9 percentage points more than in the control group.
Both groups received diabetes education and continued their previous glucose-lowering medication. That comparison supports a benefit from adding monitoring in the studied population. It does not establish universal insurance coverage, commercial retention or the amount of future sales. The business opportunity depends on converting clinical evidence into coverage decisions, clinician recommendations and sustained use.
Source: Dexcom CONNECT study announcement, June 6, 2026, trial design and reported outcomes; company-sponsored research presented at the American Diabetes Association meeting.
Competition remains substantial. Abbott reported second-quarter continuous-glucose-monitor sales growth of 11.0%, or 9.5% on its comparable basis, which removes currency effects for this business. Its broader Diabetes Care business generated $2.188 billion of sales, but that amount is not a like-for-like glucose-monitor-only comparator to Dexcom. Abbott also announced European certification for Libre Duo, combining glucose and ketone monitoring.
These disclosures show a rival with scale and continued product development. Dexcom's faster reported growth does not by itself prove market-share gains because product scope, geography, currency and customer mix differ. Better convenience and clinical results need to keep supporting customer choice as competitors improve their own products.
Source: Abbott second-quarter 2026 results, July 16, 2026, pp. 1 and 6.
Quality is the strongest operational counterevidence to a simple growth narrative. The FDA's March 4, 2025 warning letter identified deficiencies involving manufacturing controls, design controls and changes to G6 and G7 sensors. It said follow-up inspection would be needed to assess corrections. Improved margins alone do not establish that the regulatory concerns have been resolved.
Source: FDA warning letter to Dexcom, March 4, 2025, manufacturing and design observations and required corrective actions.
A separate event in May 2026 exposed a distribution-control problem. Dexcom said two lots designated for destruction were stolen and resold by third parties. One lot posed an increased skin-infection risk because sensors were not properly sterilized; the other posed an increased risk of unavailable readings because of an elevated internal testing failure rate.
Dexcom reported no associated severe adverse events at that time and said products received through authorized distributors were unaffected. The incident was limited to the identified lots, but it showed why controls over rejected products matter alongside factory quality: sensors rejected before sale still reached users.
Source: Dexcom announcement hosted by FDA, company announcement May 26, FDA publication May 29, 2026.
Management has responded with both operating changes and oversight. Alongside the manufacturing work discussed in the filing, Dexcom announced in May that its board's technology committee would become an Operations and Innovation Committee, adding focus on scaling and quality. This establishes management's intended response; it is not yet proof of the outcome.
Source: Dexcom governance announcement, May 14, 2026.
Litigation adds a related uncertainty. The filing describes securities cases about growth statements and G7 reliability, derivative actions, and consumer litigation involving G6 and G7. Five federal consumer cases had been consolidated, while a California state case remained stayed. These are allegations, not established findings against the company.
Dexcom says it cannot reasonably estimate the ultimate outcomes. The filing supplies no supportable loss range, so none can be included in a funding forecast. It also notes a California tax audit covering 2022–2023, while management expects no significant adjustment. Neither that expectation nor an absent loss estimate means the exposure is zero.
Source: 2026 Form 10-Q, Notes 5–6, p. 23; legal proceedings, pp. 41–42.
The strategic opportunity is therefore credible but conditional. Better manufacturing supports the economics, and clinical evidence supports wider use. Consistent product performance, dependable distribution and affordable access determine whether those strengths become lasting customer relationships.
8. Stronger operations fund investment, but repurchases absorb most remaining cash
Dexcom enters the second half with better operating economics and meaningful funding flexibility, but the product transition remains unfinished. The evidence supports a company earning more from growth, not merely reporting a favorable tax or financing result. It has also demonstrated that its first-half operations can cover cash equipment spending.
Management's July outlook called for 2026 revenue of $5.18–$5.25 billion, with non-GAAP gross margin near 64% and non-GAAP operating margin of 23.5%–24%. These margins use company adjustments that exclude selected expenses, so they are not directly comparable with the reported margins shown earlier.
Subtracting first-half actual revenue implies $2.680–$2.750 billion of second-half sales. That is a calculation from guidance, not an independent forecast; it requires a higher average quarterly sales level than the second quarter delivered.
Source: Dexcom July 30, 2026 results, annual guidance. Management did not reconcile forecast non-GAAP margins to GAAP because certain future adjustments could not be reasonably predicted.
The key business test is whether stronger production economics survive the remaining transition costs while more finished sensors reach paying users. Successful inventory reduction, steady collections and demonstrable quality progress would strengthen the case that the improvement can finance the next phase of expansion. Further write-downs, weaker receipts or additional remediation spending would reduce that capacity.
Repurchases are the adjustable part of this equation. Dexcom has resources to support growth and meet its commitments, but buying shares at the first-half pace leaves little internally generated cash after equipment purchases for other investments. Matching those purchases to realized cash—while preserving room for the 2028 debt maturity—would allow the improved operating business to carry more of its own expansion.
9. Higher profit, noncash adjustments and payment timing explain the cash increase
The $308.0 million operating-cash-flow increase reconciles to higher profit, noncash adjustments and changes in operating balances.
Calculation notes: Quarterly earnings, first-half cash flow and balance-sheet dates use separate, consistent comparisons. Dollar calculations below are in millions unless stated otherwise. Percentages are rounded; calculations use the displayed source amounts before rounding.
- Growth equals current-period amount divided by the same prior-year-period amount, minus one. Quarterly revenue growth is 1,308.4 / 1,157.1 − 1 = 13.1%; operating-profit growth is 318.3 / 212.6 − 1 = 49.7%; net-income growth is 249.1 / 179.8 − 1 = 38.5%. First-half growth is 14.0%, 65.6% and 57.3%, respectively.
- Gross margin is gross profit divided by revenue. Quarterly gross margin rose 3.9 percentage points; operating margin rose 6.0 percentage points using unrounded ratios. The release's rounded 590-basis-point operating-margin change reflects its presentation of rounded figures. First-half operating margin rose 7.2 percentage points using unrounded ratios.
- The quarterly operating-profit bridge is 212.6 + (830.0 − 688.8) − [(153.0 + 358.7) − (148.2 + 328.0)] = 318.3. It includes inventory reserve expense; no hypothetical reserve-free earnings measure is presented.
- First-half noncash adjustments: 2026 = 135.3 depreciation and amortization + 82.3 share compensation + 2.0 noncash interest + 0 deferred tax + 10.0 investment losses − 0.2 other = 229.4. The 2025 calculation is 123.0 + 79.5 + 3.7 − 14.7 + 4.6 − 17.3 = 178.8.
- First-half operating-asset and liability changes: 2026 = −47.5 receivables − 101.6 inventory + 31.9 prepaid and other assets − 2.3 leases + 258.0 payables and accruals − 32.1 payroll + 10.4 deferred revenue and other liabilities = 116.8. For 2025: −333.5 − 12.3 − 5.5 − 3.0 + 359.4 + 15.3 + 2.4 = 22.8.
- Operating-cash-flow improvement is 163.4 higher net income + 50.6 higher noncash adjustments + 94.0 improved operating-balance movements = 308.0. Free cash flow is 794.8 − 161.3 = 633.5, versus 486.8 − 181.1 = 305.7. Equipment purchases included in payables and accruals were 55.2 and 51.7, respectively; these are not added to the cash-spending definition.
- Investing cash flow is 994.0 − 758.7 − 161.3 − 41.2 − 1.5 = 31.3. Financing cash flow is 12.7 − 603.6 − 37.6 − 3.8 = −632.3. Opening restricted cash was 919.1 − 917.7 = 1.4; closing restricted cash was 0.2.
- Combined cash and short-term securities changed from 917.7 + 1,081.0 = 1,998.7 to 1,105.0 + 842.0 = 1,947.0. Treasury-stock cash payments used 603.6 / 633.5 = 95.3% of defined free cash flow. Remaining authorization is 1,000.0 − 600.0 = 400.0.
- Equity reconciles as 2,746.0 + 448.6 + 82.3 + 12.7 − 605.6 − 37.6 − 25.0 = 2,621.4. Accumulated other comprehensive income fell by 22.2 of translation and other losses plus 2.8 of securities losses. June assets reconcile: 6,455.3 = 3,833.9 liabilities + 2,621.4 equity. December assets reconcile: 6,339.9 = 3,593.9 + 2,746.0.
- Quarterly diluted earnings per share use 250.8 / 390.1 = approximately $0.64, versus 182.7 / 408.2 = approximately $0.45. First-half calculations use 451.9 / 391.8 and 291.0 / 407.8. These numerators add back the disclosed after-tax interest on assumed note conversions.
- Annual contractual note interest is $1,250 million × 0.375% = $4.6875 million, excluding issuance-cost amortization and other borrowing costs. Second-half revenue implied by guidance is 5,180–5,250 less 2,500.3 = 2,679.7–2,749.7; the implied quarterly average is 1,339.85–1,374.85.
Sources: 2026 Form 10-Q, pp. 4–11, Notes 3–4 and 7–8; July 30, 2026 earnings release, guidance and margin presentation.
Reporting basis: Financial amounts and calculations were checked against the consolidated statements and accompanying notes in the Form 10-Q. Quarterly, first-half and balance-sheet comparisons retain their respective periods. Dollar amounts are presented in millions unless otherwise indicated; geographic and sales-channel figures are separate breakdowns of consolidated revenue and are not added together.
Source: A machine-readable version of the filing's financial data is available in the SEC XBRL instance.
This report is for information and business analysis only. It is not investment advice.